97在线无码免费人妻短视频,国产成人成人A片在线乱码视频,欧美肥老太牲交视频,国产精品爽爽v在线观看无码

English

ENDPOINTSNEWS: On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs

2021-10-13

新聞截圖.png

— AUTHOR: Amber Tong, Senior Editor

— REPRINTED FROM ENDPOINTSNEWS

— ORIGINAL LINK: https://endpts.com/on-a-quest-to-challenge-novo-nordisk-in-obesity-transpacific-startup-picks-up-70m-and-a-pair-of-seasoned-execs/

Four years after starting Terns Pharmaceuticals together in search of an elusive NASH win, Weidong Zhong and Martijn Fenaux are reuniting at a new startup.

On paper, Sciwind Biosciences — which just raised $70 million in Series C cash — employs a similar setup as Terns: Both have embraced the transpacific model, taking root in China but planting flags in the US.

Zhong was tapped to be president of the San Francisco-based subsidiary back in July, on top of assuming the role as chief strategy officer. Weeks later, Fenaux has been appointed SVP, nonclinical development and translational science at the parent company out of Hangzhou — joining the team alongside chief scientific officer Xinle Wu, who brings experience running R&D for both Eli Lilly and Amgen in China.

Whereas Terns is focused on NASH and other liver diseases, Sciwind positions itself as a specialist in metabolic disorders. The three lead candidates all congregate around GLP-1 receptor agonism, a mechanism that Sciwind reckons is relevant across fatty liver, obesity and diabetes.

The new infusion marks Sciwind’s second financing in a year, having bagged $37 million in February to fuel the clinical work underway for XW003 (long-acting GLP-1 peptide analog) in type 2 diabetes and obesity. Topline Phase II data are expected in the second half of 2022.

To reach those massive markets, the biotech would first have to steer past giant rivals like Novo Nordisk, whose GLP-1 peptide analog semaglutide is already approved in the US for both of those indications.

Then there's the follow-on XW004, which is designed for once daily rather than once weekly administration, slated for first-in-human trials later this year; and XW014, a preclinical small molecule GLP-1R agonist.

But IDG Capital, Loyal Valley Capital and LYFE Capital have no trouble believing in Sciwind and founder/CEO Hai Pan, leading the latest round.

人妻体体内射精一区二区 | 又大又长又粗又硬又黄裸体毛片 | 国产精品午夜理论片日本 | 亚洲AV无码国产精品色字幕 | 波多野结衣无码观看 | 台湾佬娱乐官网登录入口 | 九色自慰喷白浆9 1糖心 | 亚洲天堂中文在线 | 五月天成人两性视频 | 成人在线直播观看 | 亚洲AV秘 无码一18禁 | 永久天堂V亚洲天堂 | 日本亚洲乱码欧美天堂网 | 小县城裸体舞一期二期 | 国产乱老熟妇吃嫩草成人网站 | 亚洲AV无码久久精品蜜桃动态图 | 做爰特黄AAAAAAA片 | 热99re久久精品国产首页免 | 久久人妻无码一区二区 | 羞羞视频网站在线观看 | 91丨露脸丨熟女 | 我们2019最好看中文 | 丁香五月激情综合区 | 少妇WWB搡BBBB搡BBBB小说 日韩 翘臀成人免费手机视频在线观看 | 欧美精品色婷婷五月综合 | 高潮喷射免费18禁止网站 | 国产av一区二区精品久久 | www.777777啪啪片| 黄色小视频网站在线 | 国产三级国产精品国产桃花 | 东京热无码哔哩哔哩一区二区三区 | 国产绯色在线观看 | 五月婷婷在线视频 | 国产三级精品三级在专区中文 | 国产猛男猛女超爽免费视频 | 国产拍揄自揄精品视频麻豆 | AV片免费在线观看网站 | 国产又爽又粗又猛又大爽 | 亚洲美女又黄又爽 | 国产婷婷色一区二区三区 | 福利姬视频在线观看 |